Return to homepagePandemic Pact

Silvestrol als Wirkstoff gegen SARS-CoV-2/ COVID-19

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:0 publications

Grant number: 01KI20139

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $55,870

  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)

  • Principal Investigator

    Prof. Martin Groschup

  • Research Location

    Germany

  • Lead Research Institution

    Friedrich-Loeffler-Institut, Greifswald

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

discovery - The aim of the project is to investigate whether chemically modified variants of the natural product Silvestrol are suitable for therapy against SARS-CoV-2. Previous research with SARS-CoV-2-related RNA viruses has shown that silvestrol inhibits an endogenous protein (eIF4F), which the previously examined viruses need for their multiplication in the host cells. Now the researchers want to check whether this also applies to SARS-CoV-2. To do this, they will produce chemically modified Silvestrol molecules and test their effectiveness against SARS-CoV-2 and other RNA viruses in cell cultures and in animal models. The project builds on the BMBF-funded project "16GW0203 - Preclinical Animal Model Systems" (16GW0203) in the SILVIR network. Accordingly, the preparatory work and cooperation established there can be used.